Role of β-blockers in the cardiovascular disease continuum: a collaborative Delphi survey-based consensus from Asia-Pacific

Saumitra Raya Department of Cardiology, AMRI Hospital (S), West Bengal, Kolkata, IndiaCorrespondence[email protected]

Tiny Nairb Department of Cardiology, PRS Hospital, Trivandrum, Kerala, India

Jps Sawhneyc Department of Cardiology, Member Board of Management at Sir Ganga Ram Hospital, New Delhi, India

Erwinantod Department of Cardiology and Vascular Medicine, Faculty of Medicine, Padjajaran University, Jawa Barat, Indonesia

Azhari Rosmane IJN (National Heart Institute), Johor, Malaysia

Eugene Reyesf Section of Cardiology, Department of Internal Medicine, UP-Philippine General Hospital, Manila, Philippines

Loewe Gog Internal Medicine – Cardiology, St. Luke’s Medical Center, Taguig, Philippines

Apichard Sukonthasarnh Bangkok Hospital Chiang Mai, Bangtok, Thailand

Aekarach Ariyachaipanichi Division of Cardiovascular Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Phạm Manh Hungj National Heart Institute, Bach Mai Hospital, Hanoi, Vietnam

Harshal Chaudharik Merck Specialities Pvt. Ltd., India, an affiliate of Merck KGaA, Darmstadt, Germany

Harshveer Singh Malhik Merck Specialities Pvt. Ltd., India, an affiliate of Merck KGaA, Darmstadt, Germany

show all

Role of β-blockers in the cardiovascular disease continuum: a collaborative Delphi survey-based consensus from Asia-Pacific

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Role of β-blockers in the cardiovascular disease continuum: a collaborative Delphi survey-based consensus from Asia-Pacific

Citations (1)

Read on this site (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date